CR Pharmaceutical Group Limited was set up in response to the requirement of the State-Owned Assets Supervision and Administration Commission of the State Council (SASAC) to “create a state-owned pharmaceutical platform” in 2007. It is an integrated enterprise group combining pharmaceutical R&D, manufacturing and production, as well as marketing under one umbrella. Leveraging its strong industrial base leading competitive advantages, CR Pharma is striving to “become the leader in China’s pharmaceutical industry”. In 2013, both turnover and assets of the company exceeded HK$100 billion, and CR Pharma ranked second in terms of overall strength in China’s pharmaceutical industry. On October 28, 2016, China Resources Pharmaceutical Group Limited (3320HK) was officially listed on the Hong Kong Stock Exchange.
CR Pharma owns two grade-1 profit centers, China Resources Sanjiu Medical & Pharmaceutical Co., Ltd., China Resources Double-Crane Pharmaceutical Co., Ltd., as well as famous companies including Shandong Dong-E-E-Jiao Pharmaceutical Co., Ltd., China Resources Zizhu Pharmaceutical Co., Ltd., China Resources Saike Pharmaceutical Co., Ltd., China Anhui World-Best Pharmaceutical Co., Ltd., and China Resources Pien Tze Huang Pharmaceutical Co., Ltd. Among them, CR Sanjiu (000999), CR Double-Crane, and Dong-E-E-Jiao (000423) are A-share pharmaceutical companies listed in China.
In the area of pharmaceutical manufacturing, CR Pharma is involved in natural medicine, Chinese medicine, chemical drugs, biological drugs and nutritional supplements. It ranked number one in the 2011 China Top 100 Pharmaceutical Manufacturing Enterprises, and owns well-known brands including “999”, “Double-Crane”, “Saike”, “Dong-E”, “Zizhu”, and “Yu Ting”.
In terms of retail and distribution, its business covers wholesale distribution of drugs, medical equipment, healthcare products, logistics, distribution, retail and supply chain value-added services. It ranks second among China’s pharmaceutical businesses, and is the market leader in the areas of hospital drugs distribution and extended services, and modern logistics and distribution services in China.
CR Pharma possesses abundant and quality R&D resources, and strong independent innovation capabilities. It has established two national research centers for Chinese patent medicine and traditional Chinese gelatine medicine (Ejiao series), and numerous provincial level technology centers, serving as the R&D base for birth control and genital health drugs. It is leading the industry in pharmaceutical preparation and new pharmaceutical controlled-release technologies within China, and is world-leading in its core R&D technology in pharmaceutical nucleoside intermediates. Through innovation and collaboration, CR Pharma will continue to focus on providing high-quality and reliable products and services to the public, and will strive to become the market leader in China’s pharmaceutical industry.
Turnover reaches HK$156.7billion with an operating profit of HK$9billion.
CR Sanjiu is among the “Value 100” listed companies in China.
CR Double-Crane has been awarded “Top 10 Listed Pharmaceutical Company with Best Investment Value in China”
Dong-E-E-Jiao has been awarded “Top 100 National Pharmaceutical Company”, “Top 100 National Technology Company”, and “ Top 10 Most Efficient National Pharmaceutical Company”.
“999” has been selected many times by the world’s top communications services group, WPP, as “Top 50 Most Valuable Brand in China”, “ Dong-E-E-Jiao ” has been selected as “Top 500 Most ValuableBrandinChina”.
Brands such as “999”, “Double-Crane”,“Dong-E”, “Saike”, “Zizhu”, “Yuting” and “Tianhe”, have been awarded “Most Well-Known Brands in China”.
Saike Pharmaceutical has been named as the “Leading International Enterprise” in China’s Pharmaceutical Industry.
Address: Room 4105, 41st floor, China Resources Building, 26 Harbour Road, Wanchai, Hong Kong
Tel: 00852-25938991 Fax: 00852-25938992